3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
67
Stomach Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Inflammatory Breast Neoplasms
3
Breast Neoplasms, Male
3
Solid Tumor
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
HER2-positive Breast Cancer
2
Colonic Neoplasms
2
Carcinoma, Ductal, Breast
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Neoplasms, Unknown Primary
1
Metastatic HER2-Positive Breast Cancer
1
Lung Neoplasms
1
Her2-Positive Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Elderly Metastatic Breast Cancer Population
1
Colorectal Neoplasms
1
Carcinoma, Neuroendocrine
1
Biliary Tract Neoplasms
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Unresectable or Metastatic Solid Malignancy
×
pertuzumab
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts